Detailed analysis of a randomized phase III trial: can the tolerability of capecitabine plus docetaxel be improved without compromising its survival advantage?
Titel:
Detailed analysis of a randomized phase III trial: can the tolerability of capecitabine plus docetaxel be improved without compromising its survival advantage?
Auteur:
Leonard, R. O'Shaughnessy, J. Vukelja, S. Gorbounova, V. Chan-Navarro, C.A. Maraninchi, D. Barak-Wigler, N. McKendrick, J.J. Harker, W.G. Bexon, A.S. Twelves, C.